Addex Therapeutics (XSWX:ADXN) Interest Expense : CHF-0.02 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Addex Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Addex Therapeutics's interest expense for the three months ended in Dec. 2023 was CHF -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Addex Therapeutics's Operating Income for the three months ended in Dec. 2023 was CHF -2.68 Mil. Addex Therapeutics's Interest Expense for the three months ended in Dec. 2023 was CHF -0.01 Mil. Addex Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Addex Therapeutics Interest Expense Historical Data

The historical data trend for Addex Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Addex Therapeutics Interest Expense Chart

Addex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.13

-0.07

-0.06

-0.05

-0.02

Addex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-	-	-0.01

Addex Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.02 Mil.

Addex Therapeutics (XSWX:ADXN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Addex Therapeutics's Interest Expense for the three months ended in Dec. 2023 was CHF-0.01 Mil. Its Operating Income for the three months ended in Dec. 2023 was CHF-2.68 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was CHF0.07 Mil.

Addex Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Addex Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Addex Therapeutics (XSWX:ADXN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Addex Therapeutics Ltd (XSWX:ADXN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ADXN:USA ADXNz:UK APE1:Germany

Address

Chemin des Aulx 12, Plan-les-Ouates, P.O. Box 68, Geneva, CHE, 1202

Website

https://www.addextherapeutics.com

Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.

Addex Therapeutics (XSWX:ADXN) Headlines

From GuruFocus

Thinking about buying stock in Applovin, Sonos, WiMi Hologram Cloud, Addex Therapeutics, or Snap?

By PRNewswire PRNewswire • 02-09-2023

Enamine Extend Collaboration With Prominent Swiss Biotech

By Business Wire Business Wire • 02-24-2021